Emyria Ltd (ASX:EMD) is streamlining its board with all Emyria board directors, with the exception of the managing director, moving to non-executive roles. This includes the retirement of Dr Alistair Vickery and the movement of Dr Stewart Washer to non-executive chairman from executive chairman and Dr Karen Smith to non-executive director.
Dr Vickery will shift his expertise from board responsibilities to concentrate on clinical service expansion, particularly as Emyria advances its MDMA-assisted therapy programs.
Dr Stewart Washer will transition to non-executive chairman from executive chairman and his salary will move from $200,000 per annum to a total fee of $80,000 per annum, while Dr Karen Smith will receive a salary in line with all current non-executive directors.
Halve annual board costs
Emyria is an integrated clinical drug development and care delivery firm specialising in mental health, neuropsychiatry and select neurological conditions
The changes to its board are expected to halve annual board costs, reflecting the company’s commitment to cost efficiency and a strategic focus on advancing its active MDMA-assisted therapy programs and novel drug development initiatives.
Emyria non-executive chair Dr Washer said: “We thank Dr Alistair Vickery for his invaluable contributions to the board. His insight and dedication have been a driving force behind Emyria's growth.
“As Dr Vickery transitions to focus on the clinical expansion of our MDMA-assisted therapy and mental health programs, we are confident his expertise will be instrumental in our pursuit to redefine mental health care.”